None listed
Conditions
Interventions
Drug : [Intervention group]
Opiranserin (Unafra®) 1000mg is diluted in normal saline to a total volume of 500ml and administered intravenously. Following completion of anesthesia induction, a loading
Sponsors
Yonsei University Health System, Gangnam Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients (aged 19 years or older) undergoing open gastrectomy
Exclusion criteria
Exclusion criteria: Patients with a history of allergy or hypersensitivity to local anesthetics, acetaminophen, fentanyl, opiranserin, or nefopam Patients with unstable angina or congestive heart failure, or those with QRS >200msec or QTcF >450msec on electrocardiogram Patients with moderate to severe renal impairment Patients with moderate to severe hepatic impairment Patients currently receiving drugs known to prolong PR or QRS intervals Patients currently receiving strong CYP3A4 inhibitors Patients currently receiving MAO inhibitors Patients with a history of epilepsy or seizures Patients with severe chronic pain prior to surgery Patients with a history of drug addiction Patients unable to independently operate patient-controlled analgesia (PCA) Patients with skin disease or infection at the WellPass application site Patients unable to follow instructions or respond to questionnaires due to cognitive impairment Patients unable to read the informed consent form Patients corresponding to vulnerable subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total opioid consumption up to 12 hours postoperatively (MME) | — |
Secondary
| Measure | Time frame |
|---|---|
| analgesic consumption (MME) at each postoperative time point;Pain score at each time point;Time to First Rescue Analgesic;PONV score at each time point;postoperative quality of recovery | — |
Countries
Korea, Republic of
Contacts
Public ContactJiwon Lee
Yonsei University Health System, Gangnam Severance Hospital
Outcome results
None listed